Hyloris reports full year results for 2022 & provides
Strong R&D progress & attractive commercial deals, including additional Tranexamic Acid RTU out-licensing
Globe Newswire16-03-2023, 01:08
DICE Therapeutics to Participate at Upcoming Investor 9-02-2023, 04:09